Mometasone Furoate
Momecutan contains the active substance mometasone furoate, a potent glucocorticosteroid, and is intended for external use.
Momecutan is used to treat inflammatory and itching conditions of the hairy scalp, such as psoriasis.
Before starting to use Momecutan, consult a doctor or pharmacist.
If the patient wants to use Momecutan on large skin areas or for a longer period, they must first consult a doctor.
If skin irritation or allergic reaction occurs during the use of Momecutan, consult a doctor.
If the patient experiences blurred vision or other vision disturbances, consult a doctor.
The risk of local skin infection may increase during the external use of glucocorticosteroids. If the skin becomes infected with bacteria or fungi, Momecutan should only be used under the supervision of a doctor who will take appropriate actions to combat the infections.
If the medication is used for a longer period or on large areas, under an airtight dressing, on mucous membranes, or in skin folds (elbow or knee), there is a risk of the medication being absorbed into the body. This may lead to side effects such as suppression of the hypothalamic-pituitary-adrenal axis, Cushing's syndrome (moon face, "buffalo hump"), increased blood sugar levels, or glucose in the urine. If the patient uses Momecutan on large areas or under an airtight dressing, they should consult a doctor.
If Momecutan was used for a certain period and the skin condition improved, do not suddenly stop using the medication. Abrupt cessation of the solution may cause redness, stinging, or burning. To avoid this, consult a doctor who will decide how often to apply the solution and gradually reduce the dose of the medication to complete the treatment.
Corticosteroids can change the appearance of many skin diseases, making it difficult to diagnose them and may even slow down the healing process.
Treated skin areas on the face or in children should not be covered with airtight dressings (bandages or plasters).
If the medication is used for psoriasis, close medical supervision is required.
Avoid contact with the eyes.
Due to the lack of sufficient experience, Momecutan should not be used in children under 6 years of age.
Chronic treatment with corticosteroids may affect the growth and development of children.
Tell your doctor or pharmacist about all medications you are currently using or have recently used, as well as any medications you plan to use.
If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a child, they should consult a doctor or pharmacist before using this medication.
Pregnancy
Momecutan should only be used during pregnancy on the advice of a doctor.
As with all topical glucocorticosteroids, it should be remembered that in pregnant women, the medication can pass through the placenta and may affect the unborn child.
Breastfeeding
Momecutan should only be used during breastfeeding on the advice of a doctor, but not on the breast area.
Glucocorticosteroids are excreted into human milk. If treatment with higher doses or for a longer period is necessary, breastfeeding should be discontinued.
No special precautions are required.
This medication contains 300 mg of propylene glycol per gram of solution.
This medication should always be used as directed by a doctor or pharmacist. In case of doubts, consult a doctor or pharmacist.
Momecutan is intended for use on the skin.
The recommended dose is a few drops of Momecutan once a day.
Method of use:
Apply Momecutan to the affected skin areas.
Duration of use:
Avoid using Momecutan for a long time (longer than 3 weeks) or on a large area (more than 20% of the body surface).
If improvement occurs, it is recommended to use less potent corticosteroids.
If you feel that the effect of Momecutan is too strong or too weak, consult a doctor or pharmacist.
There are insufficient clinical studies on the safety of using mometasone solution in children for a period longer than 3 weeks.
In children, Momecutan should be used for the shortest possible treatment period and with the smallest possible dose, ensuring effective treatment. In children over 6 years of age, the treatment duration is a maximum of 3 weeks. Momecutan should be used in children only on small areas (less than 10% of the body surface).
Consult a doctor immediately.
Repeated overdose or improper use of topical glucocorticosteroids, including Momecutan, may suppress the function of the adrenal cortex, which can have various consequences. However, they are reversible. If symptoms of overdose occur, the doctor will provide appropriate treatment if necessary.
Do not use a double dose to make up for a missed dose. Take the missed dose as soon as possible, and then continue with the regular dosing schedule.
Do not suddenly stop using Momecutan after long-term use, as the symptoms may return in a more severe form. The treatment should be discontinued gradually, as advised by a doctor.
In case of any further doubts about the use of this medication, consult a doctor or pharmacist.
Like all medications, Momecutan can cause side effects, although not everybody gets them.
To express the frequency of side effects, the following criteria have been used:
Very rare
folliculitis
Frequency not known
infections, furuncles
Very rare
burning sensation
Frequency not known
abnormal skin sensation (paresthesia)
Very rare
glaucoma
Frequency not known
blurred vision
Common
tingling, stinging
Uncommon
appearance of papules, pustules
Frequency not known
contact dermatitis, decreased skin pigmentation, excessive hair growth, stretch marks, acne-like skin inflammation, skin atrophy (thinning of the skin)
Very rare
skin itching (pruritus)
Frequency not known
pain at the application site, application site reactions
Very common | may affect more than 1 in 10 people |
Common | may affect up to 1 in 10 people |
Uncommon | may affect up to 1 in 100 people |
Rare | may affect up to 1 in 1,000 people |
Very rare | may affect up to 1 in 10,000 people |
Frequency not known | frequency cannot be estimated from the available data |
The following side effects have occurred in individual cases of using topical glucocorticosteroids and may also occur when using mometasone:
dry skin, skin irritation, skin inflammation, perioral dermatitis, skin maceration (softening of the skin), sweat rash, telangiectasias (dilation of blood vessels under the skin), and secondary infections (subsequent infection of the skin area previously affected by inflammation).
Other side effects with a frequency not known, which may occur in connection with topical glucocorticosteroids, include: reversible suppression of the hypothalamic-pituitary-adrenal axis, Cushing's syndrome (moon face, "buffalo hump").
Due to the larger ratio of body surface area to body mass, children and adolescents may show greater sensitivity to suppression of the adrenal cortex and the occurrence of Cushing's syndrome (adrenal insufficiency) than adult patients.
Chronic therapy with glucocorticosteroids may affect the growth and development of children.
Glucocorticosteroids can change the symptoms of diseases and make their diagnosis difficult.
The treatment process may also be delayed.
Reporting side effects
If any side effects occur, including any not mentioned in the Package Leaflet, tell your doctor or pharmacist. Side effects can be reported directly to the Department of Drug Safety Monitoring of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products:
Jerozolimskie Avenue 181C, 02-222 Warsaw, Tel.: 22 49 21 301, Fax: 22 49 21 309, website: https://smz.ezdrowie.gov.pl
By reporting side effects, more information can be collected on the safety of the medication.
Side effects can also be reported to the marketing authorization holder.
Store the medication out of sight and reach of children.
Do not use this medication after the expiry date stated on the packaging after: EXP.
The expiry date refers to the last day of the month.
Do not store above 30°C.
Caution! Flammable (aqueous-alcoholic solution)!
Shelf life after first opening the bottle: 6 months.
Medications should not be disposed of via wastewater or household waste containers. Ask your pharmacist how to dispose of medications that are no longer needed. This will help protect the environment.
The active substance of the medication is:
mometasone furoate.
1 g of solution (corresponding to 1.07 ml) contains 1 mg of mometasone furoate.
The other ingredients are:
sodium dihydrogen phosphate dihydrate, hydroxypropyl cellulose, propylene glycol, isopropyl alcohol, purified water, diluted phosphoric acid (10%).
Momecutan is a colorless, clear solution.
The medication packaging is a polyethylene bottle with a polyethylene dropper and a polyethylene cap with a tamper-evident closure, containing 20 ml, 50 ml, or 100 ml of skin solution, placed in a cardboard box.
Not all pack sizes may be marketed.
Marketing authorization holder
SUN-FARM Sp. z o.o.
Dolna 21
05-092 Łomianki
Manufacturer
mibe GmbH Arzneimittel
Münchener Strasse 15
06796 Brehna
Germany
SUN-FARM Sp. z o.o.
Dolna 21
05-092 Łomianki
Date of last revision of the Package Leaflet:09.2020
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.